Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,583021,relative bioavailability,These are the results: By intraindividual comparison of the areas under the serum fluctuation curves of canrenon a relative bioavailability of 116.27% (s = 16.84) of canrenon from Acelat 100 could be calculated versus canrenon from the standard.,[Relative bioavailability of a new spironolactone preparation (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/583021/),%,116.27,144,DB00421,Spironolactone
,23631381,absolute bioavailability,"The absolute bioavailability of 7α-TMS was significantly higher with the syrup than those obtained with the SPN-NLCs (0.7 versus 0.4, p < 0.05).","Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23631381/),,0.7,5576,DB00421,Spironolactone
,23631381,absolute bioavailability,"The absolute bioavailability of 7α-TMS was significantly higher with the syrup than those obtained with the SPN-NLCs (0.7 versus 0.4, p < 0.05).","Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23631381/),,0.4,5577,DB00421,Spironolactone
,22035978,m/,"Isoforskolin and I.S. were detected at m/z 433.4→373.3 and m/z 415.3→163.5 in positive ion and multiple reaction monitoring (MRM) mode, respectively.",A sensitive and specific HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of isoforskolin in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22035978/),,433.4,6313,DB00421,Spironolactone
,22035978,m/z,"Isoforskolin and I.S. were detected at m/z 433.4→373.3 and m/z 415.3→163.5 in positive ion and multiple reaction monitoring (MRM) mode, respectively.",A sensitive and specific HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of isoforskolin in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22035978/),,415.3,6314,DB00421,Spironolactone
,22035978,m/z,"Isoforskolin and I.S. were detected at m/z 433.4→373.3 and m/z 415.3→163.5 in positive ion and multiple reaction monitoring (MRM) mode, respectively.",A sensitive and specific HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of isoforskolin in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22035978/),,163.5,6315,DB00421,Spironolactone
less,22035978,RSDs,The RSDs were less than 6.0%.,A sensitive and specific HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of isoforskolin in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22035978/),,6,6316,DB00421,Spironolactone
,22035978,extraction recoveries,"The mean extraction recoveries of isoforskolin and I.S. were 97.0 and 88.4%, respectively.",A sensitive and specific HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of isoforskolin in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22035978/),%,97.0,6317,DB00421,Spironolactone
,22035978,extraction recoveries,"The mean extraction recoveries of isoforskolin and I.S. were 97.0 and 88.4%, respectively.",A sensitive and specific HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of isoforskolin in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22035978/),%,88.4,6318,DB00421,Spironolactone
,21039765,CL,"CL and V(d) of the typical individual in this study population (PMA = 34.6 weeks, weight = 1.7kg) were estimated to be 0.066lh(-1) kg(-1) (95% CI 0.059, 0.073lh(-1) kg(-1) ) and 0.572lkg(-1) (95% CI 0.505, 0.639lkg(-1) ), respectively.",Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21039765/),1/[kg·lh],0.066,7180,DB00421,Spironolactone
,21039765,V(d),"CL and V(d) of the typical individual in this study population (PMA = 34.6 weeks, weight = 1.7kg) were estimated to be 0.066lh(-1) kg(-1) (95% CI 0.059, 0.073lh(-1) kg(-1) ) and 0.572lkg(-1) (95% CI 0.505, 0.639lkg(-1) ), respectively.",Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21039765/),1/[lkg],0.572,7181,DB00421,Spironolactone
,12115837,AUC,"After I.V. administration of [13CD3]EP, the mean AUC of [13CD3]EP was 16.0 h. microg/mL, while the C(max), T(max), and AUC for [13CD3]SC-70303 acid were 0.744 microg/mL, 0.5 h, and 3.49 h.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),[h·μg] / [ml],16.0,19194,DB00421,Spironolactone
,12115837,C(max),"After I.V. administration of [13CD3]EP, the mean AUC of [13CD3]EP was 16.0 h. microg/mL, while the C(max), T(max), and AUC for [13CD3]SC-70303 acid were 0.744 microg/mL, 0.5 h, and 3.49 h.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),[μg] / [ml],0.744,19195,DB00421,Spironolactone
,12115837,T(max),"After I.V. administration of [13CD3]EP, the mean AUC of [13CD3]EP was 16.0 h. microg/mL, while the C(max), T(max), and AUC for [13CD3]SC-70303 acid were 0.744 microg/mL, 0.5 h, and 3.49 h.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),h,0.5,19196,DB00421,Spironolactone
,12115837,AUC,"After I.V. administration of [13CD3]EP, the mean AUC of [13CD3]EP was 16.0 h. microg/mL, while the C(max), T(max), and AUC for [13CD3]SC-70303 acid were 0.744 microg/mL, 0.5 h, and 3.49 h.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),h,3.49,19197,DB00421,Spironolactone
,12115837,AUC,"After I.V. administration of SC-70303, the AUC for SC-70303 acid was 6.36 h. microg/mL, while the C(max), T(max), and AUC for EP were 2.26 microg/mL, 0.5 h, and 9.48 h. microg/mL, respectively.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),[h·μg] / [ml],6.36,19198,DB00421,Spironolactone
,12115837,C(max),"After I.V. administration of SC-70303, the AUC for SC-70303 acid was 6.36 h. microg/mL, while the C(max), T(max), and AUC for EP were 2.26 microg/mL, 0.5 h, and 9.48 h. microg/mL, respectively.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),[μg] / [ml],2.26,19199,DB00421,Spironolactone
,12115837,T(max),"After I.V. administration of SC-70303, the AUC for SC-70303 acid was 6.36 h. microg/mL, while the C(max), T(max), and AUC for EP were 2.26 microg/mL, 0.5 h, and 9.48 h. microg/mL, respectively.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),h,0.5,19200,DB00421,Spironolactone
,12115837,AUC,"After I.V. administration of SC-70303, the AUC for SC-70303 acid was 6.36 h. microg/mL, while the C(max), T(max), and AUC for EP were 2.26 microg/mL, 0.5 h, and 9.48 h. microg/mL, respectively.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),[h·μg] / [ml],9.48,19201,DB00421,Spironolactone
,12115837,C(max),"After oral administration of [13CD3]EP, the C(max), T(max), and AUC for [13CD3]EP were 6.01 microg/mL, 0.5 h, and 27.7 h.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),[μg] / [ml],6.01,19202,DB00421,Spironolactone
,12115837,T(max),"After oral administration of [13CD3]EP, the C(max), T(max), and AUC for [13CD3]EP were 6.01 microg/mL, 0.5 h, and 27.7 h.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),h,0.5,19203,DB00421,Spironolactone
,12115837,AUC,"After oral administration of [13CD3]EP, the C(max), T(max), and AUC for [13CD3]EP were 6.01 microg/mL, 0.5 h, and 27.7 h.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),h,27.7,19204,DB00421,Spironolactone
,12115837,C(max),"After oral administration of SC-70303, the C(max), T(max), and AUC for EP were 1.38 microg/mL, 0.83 h, and 9.29 h.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),[μg] / [ml],1.38,19205,DB00421,Spironolactone
,12115837,T(max),"After oral administration of SC-70303, the C(max), T(max), and AUC for EP were 1.38 microg/mL, 0.83 h, and 9.29 h.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),h,0.83,19206,DB00421,Spironolactone
,12115837,AUC,"After oral administration of SC-70303, the C(max), T(max), and AUC for EP were 1.38 microg/mL, 0.83 h, and 9.29 h.","Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),h,9.29,19207,DB00421,Spironolactone
,12115837,systemic availability,The systemic availability was 90% for [13CD3]EP and 17.5% for SC-70303 acid.,"Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),%,90,19208,DB00421,Spironolactone
,12115837,systemic availability,The systemic availability was 90% for [13CD3]EP and 17.5% for SC-70303 acid.,"Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115837/),%,17.5,19209,DB00421,Spironolactone
,1606994,clearance,"During spironolactone treatment plasma digoxin clearance tended to be lower (255 vs 224 ml/min; P = 0.057) and renal clearance significantly lower (166 vs 144 ml/min), while the biliary clearance of digoxin remained unchanged (106 vs 103 ml/min).",Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606994/),[ml] / [min],255,25923,DB00421,Spironolactone
,1606994,clearance,"During spironolactone treatment plasma digoxin clearance tended to be lower (255 vs 224 ml/min; P = 0.057) and renal clearance significantly lower (166 vs 144 ml/min), while the biliary clearance of digoxin remained unchanged (106 vs 103 ml/min).",Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606994/),[ml] / [min],224,25924,DB00421,Spironolactone
,1606994,renal clearance,"During spironolactone treatment plasma digoxin clearance tended to be lower (255 vs 224 ml/min; P = 0.057) and renal clearance significantly lower (166 vs 144 ml/min), while the biliary clearance of digoxin remained unchanged (106 vs 103 ml/min).",Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606994/),[ml] / [min],166,25925,DB00421,Spironolactone
,1606994,renal clearance,"During spironolactone treatment plasma digoxin clearance tended to be lower (255 vs 224 ml/min; P = 0.057) and renal clearance significantly lower (166 vs 144 ml/min), while the biliary clearance of digoxin remained unchanged (106 vs 103 ml/min).",Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606994/),[ml] / [min],144,25926,DB00421,Spironolactone
,1606994,biliary clearance,"During spironolactone treatment plasma digoxin clearance tended to be lower (255 vs 224 ml/min; P = 0.057) and renal clearance significantly lower (166 vs 144 ml/min), while the biliary clearance of digoxin remained unchanged (106 vs 103 ml/min).",Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606994/),[ml] / [min],106,25927,DB00421,Spironolactone
,1606994,biliary clearance,"During spironolactone treatment plasma digoxin clearance tended to be lower (255 vs 224 ml/min; P = 0.057) and renal clearance significantly lower (166 vs 144 ml/min), while the biliary clearance of digoxin remained unchanged (106 vs 103 ml/min).",Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606994/),[ml] / [min],103,25928,DB00421,Spironolactone
,3707669,terminal elimination half-life,"Following oral multiple administration of 2.5 mg Bft (b.i.d.), the terminal elimination half-life, the steady-state volume of distribution and the total plasma clearance were determined to be 8.6-8.2 h, 0.88 l/kg and 269.4 ml/min, resp.",[Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707669/),h,8.6-8.2,27560,DB00421,Spironolactone
,3707669,steady-state volume of distribution,"Following oral multiple administration of 2.5 mg Bft (b.i.d.), the terminal elimination half-life, the steady-state volume of distribution and the total plasma clearance were determined to be 8.6-8.2 h, 0.88 l/kg and 269.4 ml/min, resp.",[Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707669/),[l] / [kg],0.88,27561,DB00421,Spironolactone
,3707669,total plasma clearance,"Following oral multiple administration of 2.5 mg Bft (b.i.d.), the terminal elimination half-life, the steady-state volume of distribution and the total plasma clearance were determined to be 8.6-8.2 h, 0.88 l/kg and 269.4 ml/min, resp.",[Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707669/),[ml] / [min],269.4,27562,DB00421,Spironolactone
,26849104,particle sizes (d50),"The particle sizes (d50) of Cil, Spi and Pro were 0.554, 0.484 and 0.377 µm, respectively, and the percentages of the nominal concentration were 79.1%, 99.6% and 75.4%, respectively.",Nanosuspension formulations of poorly water-soluble compounds for intravenous administration in exploratory toxicity studies: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849104/),µm,0.554,29621,DB00421,Spironolactone
,26849104,particle sizes (d50),"The particle sizes (d50) of Cil, Spi and Pro were 0.554, 0.484 and 0.377 µm, respectively, and the percentages of the nominal concentration were 79.1%, 99.6% and 75.4%, respectively.",Nanosuspension formulations of poorly water-soluble compounds for intravenous administration in exploratory toxicity studies: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849104/),µm,0.484,29622,DB00421,Spironolactone
,26849104,particle sizes (d50),"The particle sizes (d50) of Cil, Spi and Pro were 0.554, 0.484 and 0.377 µm, respectively, and the percentages of the nominal concentration were 79.1%, 99.6% and 75.4%, respectively.",Nanosuspension formulations of poorly water-soluble compounds for intravenous administration in exploratory toxicity studies: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849104/),µm,0.377,29623,DB00421,Spironolactone
,26849104,particle size,The particle size of Cil was 0.564 µm after storage for 16 days at 2-8 °C.,Nanosuspension formulations of poorly water-soluble compounds for intravenous administration in exploratory toxicity studies: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849104/),µm,0.564,29624,DB00421,Spironolactone
,1012347,t 1/2,"Up to the 12th h, they fell rapidly and showed a monoexponential decline (t 1/2: 2.57 +/- 0.27 days) between the 36th and 96th h.",Pharmacokinetics of spironolactone in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1012347/),d,2.57,30357,DB00421,Spironolactone
,1012347,t 1/2,"Later, a striking increase in the speed of elimination of radioactivity from plasma (t 1/2: 1.66 +/- 0.21 days) was observed.",Pharmacokinetics of spironolactone in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1012347/),d,1.66,30358,DB00421,Spironolactone
,1012347,total recovery,47-57% of the dose were excreted in urine and the remaining amount could be detected in feces (total recovery 90%).,Pharmacokinetics of spironolactone in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1012347/),%,90,30359,DB00421,Spironolactone
,1012347,t 1/2,The half-life of the urinary excretion rate was distinctly shorter (t 1/2: 0.9 +/- 0.11 days) than that of total radioactivity in plasma.,Pharmacokinetics of spironolactone in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1012347/),d,0.9,30360,DB00421,Spironolactone
,3604266,half-life,The 7 alpha-thiomethyl metabolite had a half-life of six hours in rat plasma and its AUC value was 35% of that for total 3H.,"Pharmacokinetics and metabolism of mespirenone, a new aldosterone antagonist, in rat and cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604266/),h,six,34318,DB00421,Spironolactone
,28049915,zeta potential,"The mean particle size, polydispersity index (PDI), zeta potential, solubility and encapsulation efficiency (EE) values of the SPI- and NI-loaded cubosomes were determined to be 90.4 nm, 0.187, -13.4 mV, 163 µg/mL and 90.2%, and 91.3 nm, 0.168, -12.8 mV, 189 µg/mL and 93.0%, respectively, which were almost identical to those of the blank cubosome.",Enhancing the Solubility and Oral Bioavailability of Poorly Water-Soluble Drugs Using Monoolein Cubosomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28049915/),m,0.187,35732,DB00421,Spironolactone
,28049915,solubility,"The mean particle size, polydispersity index (PDI), zeta potential, solubility and encapsulation efficiency (EE) values of the SPI- and NI-loaded cubosomes were determined to be 90.4 nm, 0.187, -13.4 mV, 163 µg/mL and 90.2%, and 91.3 nm, 0.168, -12.8 mV, 189 µg/mL and 93.0%, respectively, which were almost identical to those of the blank cubosome.",Enhancing the Solubility and Oral Bioavailability of Poorly Water-Soluble Drugs Using Monoolein Cubosomes. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28049915/),m,0.187,35733,DB00421,Spironolactone
,18787797,flow rate,"After a simple protein precipitation using methanol, the analytes were separated on a Phenomenex Luna C(18) column using 42% acetonitrile with 15 mM potassium dihydrogenphosphate in water (pH 2.0; adjusted with phosphoric acid) as the mobile phase at a flow rate of 1.2 mL/min.",Improved analytical validation and pharmacokinetics of valsartan using HPLC with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18787797/),[ml] / [min],1.2,53096,DB00421,Spironolactone
,11205738,systemic availability,"After oral administration, the systemic availability of EP was 79.2%.","Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11205738/),%,79.2,57587,DB00421,Spironolactone
,11205738,half-life,"The half-life and plasma clearance of EP were 2.21 hr and 0.329 l/kg/hr, respectively.","Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11205738/),h,2.21,57588,DB00421,Spironolactone
,11205738,plasma clearance,"The half-life and plasma clearance of EP were 2.21 hr and 0.329 l/kg/hr, respectively.","Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11205738/),[l] / [h·kg],0.329,57589,DB00421,Spironolactone
,1568578,apparent median terminal elimination rate constants (associated half-lives),"The apparent median terminal elimination rate constants (associated half-lives) were 0.0767 h-1 (9.04 hours) for SP, 0.0055 h-1 (126 hours) for 6 beta-hydroxy-7 alpha-thiomethylspirolactone, 0.029 h-1 (23.9 hours) for 7 alpha-thiomethylspirolactone and 0.012 h-1 (57.8 hours) for canrenone.",Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568578/),1/[h],0.0767,63877,DB00421,Spironolactone
,1568578,apparent median terminal elimination rate constants (associated half-lives),"The apparent median terminal elimination rate constants (associated half-lives) were 0.0767 h-1 (9.04 hours) for SP, 0.0055 h-1 (126 hours) for 6 beta-hydroxy-7 alpha-thiomethylspirolactone, 0.029 h-1 (23.9 hours) for 7 alpha-thiomethylspirolactone and 0.012 h-1 (57.8 hours) for canrenone.",Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568578/),1/[h],0.0055,63878,DB00421,Spironolactone
,1568578,apparent median terminal elimination rate constants (associated half-lives),"The apparent median terminal elimination rate constants (associated half-lives) were 0.0767 h-1 (9.04 hours) for SP, 0.0055 h-1 (126 hours) for 6 beta-hydroxy-7 alpha-thiomethylspirolactone, 0.029 h-1 (23.9 hours) for 7 alpha-thiomethylspirolactone and 0.012 h-1 (57.8 hours) for canrenone.",Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568578/),1/[h],0.029,63879,DB00421,Spironolactone
,1568578,apparent median terminal elimination rate constants (associated half-lives),"The apparent median terminal elimination rate constants (associated half-lives) were 0.0767 h-1 (9.04 hours) for SP, 0.0055 h-1 (126 hours) for 6 beta-hydroxy-7 alpha-thiomethylspirolactone, 0.029 h-1 (23.9 hours) for 7 alpha-thiomethylspirolactone and 0.012 h-1 (57.8 hours) for canrenone.",Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568578/),1/[h],0.012,63880,DB00421,Spironolactone
,27049056,relative bioavailability,"The relative bioavailability was 99.2 ± 11.6% and 97.6 ± 7.4% under fasting and fed condition, respectively.",Pharmacokinetic properties and bioequivalence of spironolactone tablets in fasting and fed healthy Chinese male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27049056/),%,99.2,67528,DB00421,Spironolactone
,27049056,relative bioavailability,"The relative bioavailability was 99.2 ± 11.6% and 97.6 ± 7.4% under fasting and fed condition, respectively.",Pharmacokinetic properties and bioequivalence of spironolactone tablets in fasting and fed healthy Chinese male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27049056/),%,97.6,67529,DB00421,Spironolactone
,7197963,maximum canrenone plasma levels,In a preliminary open bioequivalence investigation of orientating character (n =4) a single 100 mg dose of spironolactone (study I) led to maximum canrenone plasma levels (determined by HPLC) of 126.5 +/- 28.4 ng/ml (standard formulation 1) and 130 +/- 13.1 ng/ml (test formulation 2).,[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),[ng] / [ml],126.5,68183,DB00421,Spironolactone
,7197963,maximum canrenone plasma levels,In a preliminary open bioequivalence investigation of orientating character (n =4) a single 100 mg dose of spironolactone (study I) led to maximum canrenone plasma levels (determined by HPLC) of 126.5 +/- 28.4 ng/ml (standard formulation 1) and 130 +/- 13.1 ng/ml (test formulation 2).,[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),[ng] / [ml],130,68184,DB00421,Spironolactone
,7197963,minimum steady-state levels,"In a 2nd cross-over bioequivalence study with multiple dosing, mean minimum steady-state levels of 102.5 +/- 14 ng/ml (formulation 1) and 98.1 +/- 14.1 ng/ml (formulation 2) were obtained for canrenone, and 389 +/- 35.8 ng (eq)/ml (formulation 1) and 391.4 +/- 18.9 ng (eq)/ml (formulation 2) for total fluorescence.",[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),[ng] / [ml],102.5,68185,DB00421,Spironolactone
,7197963,minimum steady-state levels,"In a 2nd cross-over bioequivalence study with multiple dosing, mean minimum steady-state levels of 102.5 +/- 14 ng/ml (formulation 1) and 98.1 +/- 14.1 ng/ml (formulation 2) were obtained for canrenone, and 389 +/- 35.8 ng (eq)/ml (formulation 1) and 391.4 +/- 18.9 ng (eq)/ml (formulation 2) for total fluorescence.",[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),[ng] / [ml],98.1,68186,DB00421,Spironolactone
,7197963,minimum steady-state levels,"In a 2nd cross-over bioequivalence study with multiple dosing, mean minimum steady-state levels of 102.5 +/- 14 ng/ml (formulation 1) and 98.1 +/- 14.1 ng/ml (formulation 2) were obtained for canrenone, and 389 +/- 35.8 ng (eq)/ml (formulation 1) and 391.4 +/- 18.9 ng (eq)/ml (formulation 2) for total fluorescence.",[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),[eq·ng] / [ml],391.4,68187,DB00421,Spironolactone
,7197963,total fluorescence,"In a 2nd cross-over bioequivalence study with multiple dosing, mean minimum steady-state levels of 102.5 +/- 14 ng/ml (formulation 1) and 98.1 +/- 14.1 ng/ml (formulation 2) were obtained for canrenone, and 389 +/- 35.8 ng (eq)/ml (formulation 1) and 391.4 +/- 18.9 ng (eq)/ml (formulation 2) for total fluorescence.",[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),[eq·ng] / [ml],389,68188,DB00421,Spironolactone
,7197963,total fluorescence,"In a 2nd cross-over bioequivalence study with multiple dosing, mean minimum steady-state levels of 102.5 +/- 14 ng/ml (formulation 1) and 98.1 +/- 14.1 ng/ml (formulation 2) were obtained for canrenone, and 389 +/- 35.8 ng (eq)/ml (formulation 1) and 391.4 +/- 18.9 ng (eq)/ml (formulation 2) for total fluorescence.",[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),[eq·ng] / [ml],391.4,68189,DB00421,Spironolactone
,7197963,total fluorescence,"They were calculated to be 13226 +/-828 ng (eq)/ml . h (formulation 1) and 13858 +/- 651 ng (eq)/ml . h (formulation 2) for total fluorescence, and 3222 +/- 217 ng/ml (formulation 1) and 3167 +/- 195 ng/ml (formulation 2) for canrenone.",[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),[eq·ng] / [h·ml],13226,68190,DB00421,Spironolactone
,7197963,total fluorescence,"They were calculated to be 13226 +/-828 ng (eq)/ml . h (formulation 1) and 13858 +/- 651 ng (eq)/ml . h (formulation 2) for total fluorescence, and 3222 +/- 217 ng/ml (formulation 1) and 3167 +/- 195 ng/ml (formulation 2) for canrenone.",[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),[eq·ng] / [h·ml],13858,68191,DB00421,Spironolactone
,7197963,elimination half-lives (t 1/2),"The elimination half-lives (t 1/2) after a single 100 mg dose of spironolactone are (Study I) 16.4--19.1 h for canrenone and 13.6--14.0 h for the sum of the active (i.e., antagonistic to aldosterone) metabolites.",[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),h,16.4,68192,DB00421,Spironolactone
,7197963,elimination half-lives (t 1/2),"The elimination half-lives (t 1/2) after a single 100 mg dose of spironolactone are (Study I) 16.4--19.1 h for canrenone and 13.6--14.0 h for the sum of the active (i.e., antagonistic to aldosterone) metabolites.",[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),h,13.6,68193,DB00421,Spironolactone
,7197963,tau,"Certain therapeutic conditions (e.g. multiple dosing of 100 mg spironolactone with tau = 12 h, Study II) can lead to slightly increased t 1/2 values for both canrenone (18.6--21.4 (h)) and total fluorogenic metabolites (15.8--16.9 (h)).",[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),h,12,68194,DB00421,Spironolactone
,7197963,t 1/2,"Certain therapeutic conditions (e.g. multiple dosing of 100 mg spironolactone with tau = 12 h, Study II) can lead to slightly increased t 1/2 values for both canrenone (18.6--21.4 (h)) and total fluorogenic metabolites (15.8--16.9 (h)).",[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),,18.6,68195,DB00421,Spironolactone
,7197963,t 1/2,"Certain therapeutic conditions (e.g. multiple dosing of 100 mg spironolactone with tau = 12 h, Study II) can lead to slightly increased t 1/2 values for both canrenone (18.6--21.4 (h)) and total fluorogenic metabolites (15.8--16.9 (h)).",[Bioavailability studies of two spironolactone-preparations (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197963/),,15.8,68196,DB00421,Spironolactone
,19806919,t1/2,"The main pharmacokinetic parameters of EP after oral administration of 25 mg, 50 mg, 100 mg were as follows, t1/2: (4.9 +/- 2.1), (4.7 +/- 1.5), (5.9 +/- 1.2) h; AUC(0-infinity): (4 402 +/- 1 735), (8 150 +/- 2 509), (13 783 +/- 4 102) microg x h x L(-1); and MRT: (6.2 +/- 2.1), (6.6 +/- 1.3), and (7.2 +/- 1.6) h.",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),h,4.9,69125,DB00421,Spironolactone
,19806919,t1/2,"The main pharmacokinetic parameters of EP after oral administration of 25 mg, 50 mg, 100 mg were as follows, t1/2: (4.9 +/- 2.1), (4.7 +/- 1.5), (5.9 +/- 1.2) h; AUC(0-infinity): (4 402 +/- 1 735), (8 150 +/- 2 509), (13 783 +/- 4 102) microg x h x L(-1); and MRT: (6.2 +/- 2.1), (6.6 +/- 1.3), and (7.2 +/- 1.6) h.",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),h,4.7,69126,DB00421,Spironolactone
,19806919,t1/2,"The main pharmacokinetic parameters of EP after oral administration of 25 mg, 50 mg, 100 mg were as follows, t1/2: (4.9 +/- 2.1), (4.7 +/- 1.5), (5.9 +/- 1.2) h; AUC(0-infinity): (4 402 +/- 1 735), (8 150 +/- 2 509), (13 783 +/- 4 102) microg x h x L(-1); and MRT: (6.2 +/- 2.1), (6.6 +/- 1.3), and (7.2 +/- 1.6) h.",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),h,5.9,69127,DB00421,Spironolactone
,19806919,AUC(0-infinity),"The main pharmacokinetic parameters of EP after oral administration of 25 mg, 50 mg, 100 mg were as follows, t1/2: (4.9 +/- 2.1), (4.7 +/- 1.5), (5.9 +/- 1.2) h; AUC(0-infinity): (4 402 +/- 1 735), (8 150 +/- 2 509), (13 783 +/- 4 102) microg x h x L(-1); and MRT: (6.2 +/- 2.1), (6.6 +/- 1.3), and (7.2 +/- 1.6) h.",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),[h·μg] / [l],4 402,69128,DB00421,Spironolactone
,19806919,AUC(0-infinity),"The main pharmacokinetic parameters of EP after oral administration of 25 mg, 50 mg, 100 mg were as follows, t1/2: (4.9 +/- 2.1), (4.7 +/- 1.5), (5.9 +/- 1.2) h; AUC(0-infinity): (4 402 +/- 1 735), (8 150 +/- 2 509), (13 783 +/- 4 102) microg x h x L(-1); and MRT: (6.2 +/- 2.1), (6.6 +/- 1.3), and (7.2 +/- 1.6) h.",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),[h·μg] / [l],8 150,69129,DB00421,Spironolactone
,19806919,AUC(0-infinity),"The main pharmacokinetic parameters of EP after oral administration of 25 mg, 50 mg, 100 mg were as follows, t1/2: (4.9 +/- 2.1), (4.7 +/- 1.5), (5.9 +/- 1.2) h; AUC(0-infinity): (4 402 +/- 1 735), (8 150 +/- 2 509), (13 783 +/- 4 102) microg x h x L(-1); and MRT: (6.2 +/- 2.1), (6.6 +/- 1.3), and (7.2 +/- 1.6) h.",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),[h·μg] / [l],13 783,69130,DB00421,Spironolactone
,19806919,MRT,"The main pharmacokinetic parameters of EP after oral administration of 25 mg, 50 mg, 100 mg were as follows, t1/2: (4.9 +/- 2.1), (4.7 +/- 1.5), (5.9 +/- 1.2) h; AUC(0-infinity): (4 402 +/- 1 735), (8 150 +/- 2 509), (13 783 +/- 4 102) microg x h x L(-1); and MRT: (6.2 +/- 2.1), (6.6 +/- 1.3), and (7.2 +/- 1.6) h.",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),h,6.2,69131,DB00421,Spironolactone
,19806919,MRT,"The main pharmacokinetic parameters of EP after oral administration of 25 mg, 50 mg, 100 mg were as follows, t1/2: (4.9 +/- 2.1), (4.7 +/- 1.5), (5.9 +/- 1.2) h; AUC(0-infinity): (4 402 +/- 1 735), (8 150 +/- 2 509), (13 783 +/- 4 102) microg x h x L(-1); and MRT: (6.2 +/- 2.1), (6.6 +/- 1.3), and (7.2 +/- 1.6) h.",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),h,6.6,69132,DB00421,Spironolactone
,19806919,MRT,"The main pharmacokinetic parameters of EP after oral administration of 25 mg, 50 mg, 100 mg were as follows, t1/2: (4.9 +/- 2.1), (4.7 +/- 1.5), (5.9 +/- 1.2) h; AUC(0-infinity): (4 402 +/- 1 735), (8 150 +/- 2 509), (13 783 +/- 4 102) microg x h x L(-1); and MRT: (6.2 +/- 2.1), (6.6 +/- 1.3), and (7.2 +/- 1.6) h.",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),h,7.2,69133,DB00421,Spironolactone
,19806919,t1/2,"Parameters of EP after oral administration of multiple doses of 50 mg were as follows, t1/2: (6.1 +/- 1.7) h; AUC(ss): (10 071 +/- 4220) microg x h x L(-1); MRT: (8.1 +/- 2.3) h; and DF: (3.2 +/- 1.0).",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),h,6.1,69134,DB00421,Spironolactone
,19806919,AUC(ss),"Parameters of EP after oral administration of multiple doses of 50 mg were as follows, t1/2: (6.1 +/- 1.7) h; AUC(ss): (10 071 +/- 4220) microg x h x L(-1); MRT: (8.1 +/- 2.3) h; and DF: (3.2 +/- 1.0).",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),[h·μg] / [l],10 071,69135,DB00421,Spironolactone
,19806919,MRT,"Parameters of EP after oral administration of multiple doses of 50 mg were as follows, t1/2: (6.1 +/- 1.7) h; AUC(ss): (10 071 +/- 4220) microg x h x L(-1); MRT: (8.1 +/- 2.3) h; and DF: (3.2 +/- 1.0).",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),h,8.1,69136,DB00421,Spironolactone
,19806919,DF,"Parameters of EP after oral administration of multiple doses of 50 mg were as follows, t1/2: (6.1 +/- 1.7) h; AUC(ss): (10 071 +/- 4220) microg x h x L(-1); MRT: (8.1 +/- 2.3) h; and DF: (3.2 +/- 1.0).",Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806919/),,3.2,69137,DB00421,Spironolactone
above,8818057,recovery,The recovery was above 80% for all investigated compounds and for the internal standard.,Simultaneous determination of spironolactone and its metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818057/),%,80,73197,DB00421,Spironolactone
,8080005,Prenin,"The creatinine clearance fell (from 90.5 +/- 16.8 to 65.8 +/- 20.9 ml/min; p < 0.05), and Prenin rose (from 16.6 +/- 8.9 to 35.3 +/- 25.3 ng/ml/h; p < 0.02, as did Paldo (from 26.1 +/- 12.3 to 109 +/- 82.6 ng/dl; p < 0.01), indicating extracellular fluid volume contraction; however no significant clinical symptoms of hypovolemia ensued.",Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8080005/),[ng] / [h·ml],16.6,84182,DB00421,Spironolactone
,8080005,Prenin,"The creatinine clearance fell (from 90.5 +/- 16.8 to 65.8 +/- 20.9 ml/min; p < 0.05), and Prenin rose (from 16.6 +/- 8.9 to 35.3 +/- 25.3 ng/ml/h; p < 0.02, as did Paldo (from 26.1 +/- 12.3 to 109 +/- 82.6 ng/dl; p < 0.01), indicating extracellular fluid volume contraction; however no significant clinical symptoms of hypovolemia ensued.",Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8080005/),[ng] / [h·ml],35.3,84183,DB00421,Spironolactone
,8080005,Paldo,"The creatinine clearance fell (from 90.5 +/- 16.8 to 65.8 +/- 20.9 ml/min; p < 0.05), and Prenin rose (from 16.6 +/- 8.9 to 35.3 +/- 25.3 ng/ml/h; p < 0.02, as did Paldo (from 26.1 +/- 12.3 to 109 +/- 82.6 ng/dl; p < 0.01), indicating extracellular fluid volume contraction; however no significant clinical symptoms of hypovolemia ensued.",Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8080005/),[ng] / [dl],26.1,84184,DB00421,Spironolactone
,8080005,Paldo,"The creatinine clearance fell (from 90.5 +/- 16.8 to 65.8 +/- 20.9 ml/min; p < 0.05), and Prenin rose (from 16.6 +/- 8.9 to 35.3 +/- 25.3 ng/ml/h; p < 0.02, as did Paldo (from 26.1 +/- 12.3 to 109 +/- 82.6 ng/dl; p < 0.01), indicating extracellular fluid volume contraction; however no significant clinical symptoms of hypovolemia ensued.",Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8080005/),[ng] / [dl],109,84185,DB00421,Spironolactone
,11707062,V1,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [kg],1.83,85950,DB00421,Spironolactone
,11707062,V2,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [kg],22.6,85951,DB00421,Spironolactone
,11707062,Q,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [h·kg],0.629,85952,DB00421,Spironolactone
,9266289,"tss,max","For tss,max nonparametric 90% confidence intervals were determined as 0.00 to 1.50 h for spironolactone and canrenone and as -0.50 to 1.00 h for 7 alpha-thiomethylspirolactone.",Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266289/),h,0.00 to 1.50,93971,DB00421,Spironolactone
,9266289,"tss,max","For tss,max nonparametric 90% confidence intervals were determined as 0.00 to 1.50 h for spironolactone and canrenone and as -0.50 to 1.00 h for 7 alpha-thiomethylspirolactone.",Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266289/),h,-0.50 to 1.00,93972,DB00421,Spironolactone
,1261154,peak plasma level,"After a 200-mg oral dose of the drug given in a solution of polyethylene glycol-400, the peak plasma level of the dethioacetylated metabolite canrenone was 633 +/- 154 ng/ml (mean +/- SD) and was reached at 1.4 +/- 0.43 hr.",Spironolactone. II. Bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261154/),[ng] / [ml],633,117922,DB00421,Spironolactone
,1261154,peak,This peak was higher and was achieved earlier than after either eight 25-mg tablets (480 +/- 155 ng/ml at 2.9 +/- 1.03 hr) or two 100-mg tablets (474 +/- 182 ng/ml at 3.0 +/- 1.37 hr).,Spironolactone. II. Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261154/),[ng] / [ml],480,117923,DB00421,Spironolactone
,1261154,peak,This peak was higher and was achieved earlier than after either eight 25-mg tablets (480 +/- 155 ng/ml at 2.9 +/- 1.03 hr) or two 100-mg tablets (474 +/- 182 ng/ml at 3.0 +/- 1.37 hr).,Spironolactone. II. Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261154/),[ng] / [ml],474,117924,DB00421,Spironolactone
,1261154,bioavailabilities,"From the ratio of the 24-hr area under the plasma concentration-time curves, the bioavailabilities of the two tablet preparations relative to the solution were 99.6 +/- 18.2% and 92.1 +/- 22.9%, respectively.",Spironolactone. II. Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261154/),%,99.6,117925,DB00421,Spironolactone
,1261154,bioavailabilities,"From the ratio of the 24-hr area under the plasma concentration-time curves, the bioavailabilities of the two tablet preparations relative to the solution were 99.6 +/- 18.2% and 92.1 +/- 22.9%, respectively.",Spironolactone. II. Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261154/),%,92.1,117926,DB00421,Spironolactone
,20304966,IC(50),"IC(50) values for spironolactone and canrenone ranged from 26 to 50 microM, whereas canrenoic acid was a weak inhibitor.",Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20304966/),μM,26 to 50,118214,DB00421,Spironolactone
,20304966,K(i),"Mean (+/-) K(i) values for spironolactone were 52 +/- 22 (HLM) and 34 +/- 4 microM (HKCM), and mean (+/-) K(i) values for canrenone were 41 +/- 19 (HLM) and 23 +/- 2 microM (HKCM).",Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20304966/),μM,52,118215,DB00421,Spironolactone
,20304966,K(i),"Mean (+/-) K(i) values for spironolactone were 52 +/- 22 (HLM) and 34 +/- 4 microM (HKCM), and mean (+/-) K(i) values for canrenone were 41 +/- 19 (HLM) and 23 +/- 2 microM (HKCM).",Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20304966/),μM,34,118216,DB00421,Spironolactone
,20304966,K(i),"Mean (+/-) K(i) values for spironolactone were 52 +/- 22 (HLM) and 34 +/- 4 microM (HKCM), and mean (+/-) K(i) values for canrenone were 41 +/- 19 (HLM) and 23 +/- 2 microM (HKCM).",Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20304966/),μM,41,118217,DB00421,Spironolactone
,20304966,K(i),"Mean (+/-) K(i) values for spironolactone were 52 +/- 22 (HLM) and 34 +/- 4 microM (HKCM), and mean (+/-) K(i) values for canrenone were 41 +/- 19 (HLM) and 23 +/- 2 microM (HKCM).",Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20304966/),μM,23,118218,DB00421,Spironolactone
,20304966,K(i),"K(i) values for spironolactone and canrenone inhibition of ALDO 18beta-glucuronidation by recombinant UGT2B7 were 23 and 11 microM, respectively.",Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20304966/),μM,23,118219,DB00421,Spironolactone
,20304966,K(i),"K(i) values for spironolactone and canrenone inhibition of ALDO 18beta-glucuronidation by recombinant UGT2B7 were 23 and 11 microM, respectively.",Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20304966/),μM,11,118220,DB00421,Spironolactone
,20304966,K(i),"""Actual"" K(i) values for spironolactone and canrenone inhibition of ALDO 18beta-glucuronidation, which take into account the role of endogenous microsomal inhibitors, are predicted to be 3 to 5 and 2 to 4 microM, respectively.",Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20304966/),μM,3 to 5,118221,DB00421,Spironolactone
,20304966,K(i),"""Actual"" K(i) values for spironolactone and canrenone inhibition of ALDO 18beta-glucuronidation, which take into account the role of endogenous microsomal inhibitors, are predicted to be 3 to 5 and 2 to 4 microM, respectively.",Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20304966/),μM,2 to 4,118222,DB00421,Spironolactone
,20523346,Ka,The final model formula is Cl/F=5.9x[1-0.412 x SPI] x [1-0.0101x(WT-62.9)] x [1-0.0012x(Cr-126.8)] (L/h); Ka=1.63 (h(-1)); V(d)/F=550 (L).,Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523346/),,1.63,119245,DB00421,Spironolactone
,20523346,V(d)/F,The final model formula is Cl/F=5.9x[1-0.412 x SPI] x [1-0.0101x(WT-62.9)] x [1-0.0012x(Cr-126.8)] (L/h); Ka=1.63 (h(-1)); V(d)/F=550 (L).,Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523346/),l,550,119246,DB00421,Spironolactone
,20523346,Cl/F,"The population estimates for Cl/F and V(d)/F were 5.9 L/h and 550 L, respectively.",Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523346/),[l] / [h],5.9,119247,DB00421,Spironolactone
,20523346,V(d)/F,"The population estimates for Cl/F and V(d)/F were 5.9 L/h and 550 L, respectively.",Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523346/),l,550,119248,DB00421,Spironolactone
,26262771,C max,"After single-dose oral administration, the mean C max value increased from 489 to 1 641 ng/mL, and the mean AUC 0-t value increased from 3 030 to 10 893 ng/mL·h with an increase in dose from 25 to 100 mg, respectively.",Dose Proportionality and Pharmacokinetics of Eplerenone in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26262771/),[ng] / [ml],489 to 1 641,120639,DB00421,Spironolactone
,26262771,AUC 0-t,"After single-dose oral administration, the mean C max value increased from 489 to 1 641 ng/mL, and the mean AUC 0-t value increased from 3 030 to 10 893 ng/mL·h with an increase in dose from 25 to 100 mg, respectively.",Dose Proportionality and Pharmacokinetics of Eplerenone in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26262771/),[ng] / [h·ml],3,120640,DB00421,Spironolactone
,26262771,terminal T 1/2,The mean value for terminal T 1/2 was approximate 3 h with no significant differences among different dose groups.,Dose Proportionality and Pharmacokinetics of Eplerenone in Healthy Chinese Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26262771/),h,3,120641,DB00421,Spironolactone
,15930762,apparent first-order rate constants (k(obs)),"The apparent first-order rate constants (k(obs)) at 37, 23.5 and 0 degrees C were 3.543+/-0.261 (h-1, mean+/-S.D., n=3), 6.278+/-0.045 (x10(-1) h-1), and 7.336+/-0.843 (x10(-2) h-1), respectively.",Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930762/),,3.543,120801,DB00421,Spironolactone
,15930762,apparent first-order rate constants (k(obs)),"The apparent first-order rate constants (k(obs)) at 37, 23.5 and 0 degrees C were 3.543+/-0.261 (h-1, mean+/-S.D., n=3), 6.278+/-0.045 (x10(-1) h-1), and 7.336+/-0.843 (x10(-2) h-1), respectively.",Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930762/),1/[10·h],6.278,120802,DB00421,Spironolactone
,15930762,apparent first-order rate constants (k(obs)),"The apparent first-order rate constants (k(obs)) at 37, 23.5 and 0 degrees C were 3.543+/-0.261 (h-1, mean+/-S.D., n=3), 6.278+/-0.045 (x10(-1) h-1), and 7.336+/-0.843 (x10(-2) h-1), respectively.",Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930762/),1/[(10)^2·h],7.336,120803,DB00421,Spironolactone
,15930762,half-lives,"The half-lives were 0.20 h, 1.10 h, and 9.53 h.",Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930762/),h,0.20,120804,DB00421,Spironolactone
,15930762,half-lives,"The half-lives were 0.20 h, 1.10 h, and 9.53 h.",Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930762/),h,1.10,120805,DB00421,Spironolactone
,15930762,half-lives,"The half-lives were 0.20 h, 1.10 h, and 9.53 h.",Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930762/),h,9.53,120806,DB00421,Spironolactone
,15930762,AUC,"The AUC, MRT, CL and Vd(ss) values (mean+/-S.E. of 4 rats) for SPN were 4100.8+/-212.9 ng h/ml, 0.29+/-0.01 h, 4915.7+/-248.0 ml/h/kg, and 1435.4+/-48.4 ml/kg, respectively.",Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930762/),[h·ng] / [ml],4100.8,120807,DB00421,Spironolactone
,15930762,Vd(ss),"The AUC, MRT, CL and Vd(ss) values (mean+/-S.E. of 4 rats) for SPN were 4100.8+/-212.9 ng h/ml, 0.29+/-0.01 h, 4915.7+/-248.0 ml/h/kg, and 1435.4+/-48.4 ml/kg, respectively.",Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930762/),[ml] / [kg],1435.4,120808,DB00421,Spironolactone
,15930762,AUC,"The AUC, MRT, Cmax and Tmax values (mean+/-S.E. of 4 rats) of canrenone, an active metabolite of SPN, after the administration of SPN were 4196.1+/-787.5 ng h/ml, 1.99+/-0.13 h, 1546.3+/-436.4 ng/ml and 1.0+/-0.0 h, respectively.",Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930762/),[h·ng] / [ml],4196.1,120809,DB00421,Spironolactone
,15930762,MRT,"The AUC, MRT, Cmax and Tmax values (mean+/-S.E. of 4 rats) of canrenone, an active metabolite of SPN, after the administration of SPN were 4196.1+/-787.5 ng h/ml, 1.99+/-0.13 h, 1546.3+/-436.4 ng/ml and 1.0+/-0.0 h, respectively.",Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930762/),[ng] / [ml],1546.3,120810,DB00421,Spironolactone
,15930762,Cmax,"The AUC, MRT, Cmax and Tmax values (mean+/-S.E. of 4 rats) of canrenone, an active metabolite of SPN, after the administration of SPN were 4196.1+/-787.5 ng h/ml, 1.99+/-0.13 h, 1546.3+/-436.4 ng/ml and 1.0+/-0.0 h, respectively.",Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930762/),[ng] / [ml],1546.3,120811,DB00421,Spironolactone
,15930762,Tmax,"The AUC, MRT, Cmax and Tmax values (mean+/-S.E. of 4 rats) of canrenone, an active metabolite of SPN, after the administration of SPN were 4196.1+/-787.5 ng h/ml, 1.99+/-0.13 h, 1546.3+/-436.4 ng/ml and 1.0+/-0.0 h, respectively.",Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930762/),h,1.0,120812,DB00421,Spironolactone
,20557443,ED(50)),The dose of spironolactone required to inhibit the action of aldosterone by 50% (ED(50)) was estimated to be 1.08 +/- 0.28 mg/kg.,A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20557443/),[mg] / [kg],1.08,122918,DB00421,Spironolactone
,9241094,relative bioavailability,"The mean (95% confidence limits) relative bioavailability for SP-COMP (compared with ALD) from steady state serum concentrations of canrenone, 6beta-hydroxyl 7alpha-thiomethyl spironolactone and 7alpha-thiomethyl spironolactone was 310.0 (265.4, 336.7), 233.4(212.9, 250.8) and 254.8(230.8, 279.0)%, respectively.",Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241094/),%,310.0,125732,DB00421,Spironolactone
,9241094,relative bioavailability,"The mean (95% confidence limits) relative bioavailability for SP-COMP (compared with ALD) from steady state serum concentrations of canrenone, 6beta-hydroxyl 7alpha-thiomethyl spironolactone and 7alpha-thiomethyl spironolactone was 310.0 (265.4, 336.7), 233.4(212.9, 250.8) and 254.8(230.8, 279.0)%, respectively.",Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241094/),%,233.4,125733,DB00421,Spironolactone
,9241094,relative bioavailability,"The mean (95% confidence limits) relative bioavailability for SP-COMP (compared with ALD) from steady state serum concentrations of canrenone, 6beta-hydroxyl 7alpha-thiomethyl spironolactone and 7alpha-thiomethyl spironolactone was 310.0 (265.4, 336.7), 233.4(212.9, 250.8) and 254.8(230.8, 279.0)%, respectively.",Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241094/),%,254.8,125734,DB00421,Spironolactone
,1143356,half-life,"In plasma, the concentrations of total radioactivity are reduced in pretreated animals to about 20% of tritium levels in control rats, while the half-life of radioactivity in both groups is almost identical, 2.9 days in pretreated rats and 2.8 days in controls.",Influence of spironolactone pretreatment on pharmacokinetics and metabolism of digitoxin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1143356/),d,2.9,131936,DB00421,Spironolactone
,1143356,half-life,"In plasma, the concentrations of total radioactivity are reduced in pretreated animals to about 20% of tritium levels in control rats, while the half-life of radioactivity in both groups is almost identical, 2.9 days in pretreated rats and 2.8 days in controls.",Influence of spironolactone pretreatment on pharmacokinetics and metabolism of digitoxin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1143356/),d,2.8,131937,DB00421,Spironolactone
,6653638,maximum plasma level,"Following intravenous administration, the maximum plasma level of 2066 +/- 876 ng/ml was found after 29 +/- 15 min and thereafter the concentration declined with a half-life of 3.7 +/- 1.2 h.",Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653638/),[ng] / [ml],2066,136606,DB00421,Spironolactone
,6653638,half-life,"Following intravenous administration, the maximum plasma level of 2066 +/- 876 ng/ml was found after 29 +/- 15 min and thereafter the concentration declined with a half-life of 3.7 +/- 1.2 h.",Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653638/),h,3.7,136607,DB00421,Spironolactone
,6653638,Total clearance,Total clearance was 4.2 +/- 1.7 ml/min .,Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653638/),[ml] / [min],4.2,136608,DB00421,Spironolactone
,6653638,maximum concentration,"After oral ingestion, the maximum concentration of 177 +/- 33 ng/ml was observed at 4.4 +/- 0.9 h.",Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653638/),[ng] / [ml],177,136609,DB00421,Spironolactone
,6653638,absolute bioavailability,The absolute bioavailability of canrenone was 25 +/- 9%.,Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653638/),%,25,136610,DB00421,Spironolactone
,6653638,half-life of elimination,The half-life of elimination was 4.9 +/- 1.8 h (i.v.) and 3.9 +/- 1.2 h (p.o.).,Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653638/),h,4.9,136611,DB00421,Spironolactone
,6653638,half-life of elimination,The half-life of elimination was 4.9 +/- 1.8 h (i.v.) and 3.9 +/- 1.2 h (p.o.).,Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653638/),h,3.9,136612,DB00421,Spironolactone
,32153059,apparent clearance,"The estimated value of apparent clearance in a typical individual standardized by mean weight ranged between 0.24 and 0.56 L/h/kg, the interindividual variability in clearance ranged between 7.0 and 35.1%.",A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32153059/),[l] / [h·kg],0.24 and 0.56,139026,DB00421,Spironolactone
,12637247,elimination half-life,"2. Following a single i.v. dose (15 mg kg(-1)), the elimination half-life of EP was 0.80 and 1.14 h in male and female rats, respectively.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),h,0.80,145548,DB00421,Spironolactone
,12637247,elimination half-life,"2. Following a single i.v. dose (15 mg kg(-1)), the elimination half-life of EP was 0.80 and 1.14 h in male and female rats, respectively.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),h,1.14,145549,DB00421,Spironolactone
,12637247,Plasma clearances (CL),"Plasma clearances (CL) of EP were 1.62 and 1.20 l kg(-1) h(-1) in males and females, respectively.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),[l] / [h·kg],1.62,145550,DB00421,Spironolactone
,12637247,Plasma clearances (CL),"Plasma clearances (CL) of EP were 1.62 and 1.20 l kg(-1) h(-1) in males and females, respectively.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),[l] / [h·kg],1.20,145551,DB00421,Spironolactone
,12637247,C(max),"Following a single oral dose (15 mg kg(-1)), C(max) and T(max) of EP were 1.71 micro g ml(-1) and 0.5 h in male rats.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),[μg] / [ml],1.71,145552,DB00421,Spironolactone
,12637247,T(max),"Following a single oral dose (15 mg kg(-1)), C(max) and T(max) of EP were 1.71 micro g ml(-1) and 0.5 h in male rats.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),h,0.5,145553,DB00421,Spironolactone
,12637247,systemic availability,"The systemic availability of EP was 25.6% in male rats and 66.4% in female rats, demonstrating sex differences in the pharmacokinetics of EP.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),%,25.6,145554,DB00421,Spironolactone
,12637247,systemic availability,"The systemic availability of EP was 25.6% in male rats and 66.4% in female rats, demonstrating sex differences in the pharmacokinetics of EP.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),%,66.4,145555,DB00421,Spironolactone
,7592177,terminal elimination constant,The following mean pharmacokinetic parameters were found for the patient group: terminal elimination constant 0.0101/h (normal 0.0214/h); mean residence time 134 h (normal 46.7h); area under the curve 200 h.mg/L(normal 69.4 h.mg/L); plasma clearance 0.96 L/h.kg(normal 2.16 L/h.kg).,Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7592177/),1/[h],0.0101,152104,DB00421,Spironolactone
,7592177,mean residence time,The following mean pharmacokinetic parameters were found for the patient group: terminal elimination constant 0.0101/h (normal 0.0214/h); mean residence time 134 h (normal 46.7h); area under the curve 200 h.mg/L(normal 69.4 h.mg/L); plasma clearance 0.96 L/h.kg(normal 2.16 L/h.kg).,Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7592177/),h,134,152105,DB00421,Spironolactone
,7592177,area under the curve,The following mean pharmacokinetic parameters were found for the patient group: terminal elimination constant 0.0101/h (normal 0.0214/h); mean residence time 134 h (normal 46.7h); area under the curve 200 h.mg/L(normal 69.4 h.mg/L); plasma clearance 0.96 L/h.kg(normal 2.16 L/h.kg).,Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7592177/),[h·mg] / [l],200,152106,DB00421,Spironolactone
,7592177,plasma clearance,The following mean pharmacokinetic parameters were found for the patient group: terminal elimination constant 0.0101/h (normal 0.0214/h); mean residence time 134 h (normal 46.7h); area under the curve 200 h.mg/L(normal 69.4 h.mg/L); plasma clearance 0.96 L/h.kg(normal 2.16 L/h.kg).,Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7592177/),[l] / [h·kg],0.96,152107,DB00421,Spironolactone
,27185599,extraction recovery rates,The extraction recovery rates ranged from 91.96% to 94.96%.,Pharmacokinetic study of eplerenone in rats after long-term coadministration with buckwheat tea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185599/),%,91.96,162020,DB00421,Spironolactone
,27185599,extraction recovery rates,The extraction recovery rates ranged from 91.96% to 94.96%.,Pharmacokinetic study of eplerenone in rats after long-term coadministration with buckwheat tea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185599/),%,94.96,162021,DB00421,Spironolactone
,2080486,Tmax,Plasma curves show Tmax respectively equal to 1.19 +/- 0.47 hours (1 tablet) or 1.21 +/- 0.46 (2 tablets).,[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),h,1.19,162271,DB00421,Spironolactone
,2080486,Tmax,Plasma curves show Tmax respectively equal to 1.19 +/- 0.47 hours (1 tablet) or 1.21 +/- 0.46 (2 tablets).,[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),,1.21,162272,DB00421,Spironolactone
,2080486,Tmax,"Spironolactone is rapidly metabolized as it is shown by the mean Tmax of metabolites: 7TM and CAN Tmax are respectively 1.56 +/- 0.45 hours and 2.54 +/- 1.06 hours after administration of 1 tablet, or 1.58 +/- 0.42 hours and 2.67 +/- 1.13 hours after administration of 2 tablets.",[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),h,1.56,162273,DB00421,Spironolactone
,2080486,Tmax,"Spironolactone is rapidly metabolized as it is shown by the mean Tmax of metabolites: 7TM and CAN Tmax are respectively 1.56 +/- 0.45 hours and 2.54 +/- 1.06 hours after administration of 1 tablet, or 1.58 +/- 0.42 hours and 2.67 +/- 1.13 hours after administration of 2 tablets.",[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),h,1.58,162274,DB00421,Spironolactone
,2080486,Tmax,"Spironolactone is rapidly metabolized as it is shown by the mean Tmax of metabolites: 7TM and CAN Tmax are respectively 1.56 +/- 0.45 hours and 2.54 +/- 1.06 hours after administration of 1 tablet, or 1.58 +/- 0.42 hours and 2.67 +/- 1.13 hours after administration of 2 tablets.",[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),h,2.67,162275,DB00421,Spironolactone
,2080486,Tmax,"Spironolactone is rapidly metabolized as it is shown by the mean Tmax of metabolites: 7TM and CAN Tmax are respectively 1.56 +/- 0.45 hours and 2.54 +/- 1.06 hours after administration of 1 tablet, or 1.58 +/- 0.42 hours and 2.67 +/- 1.13 hours after administration of 2 tablets.",[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),h,2.54,162276,DB00421,Spironolactone
,2080486,mean residence time (MRT),The mean residence time (MRT) of ALT [4.94 +/- 1.14 hours (1 tablet) or 5.31 +/- 1.06 hours (2 tablets)] and SPI [1.81 +/- 0.45 hours (1 tablet) or 1.88 +/- 0.50 hours (2 tablets)] shows a rapid elimination of both drugs.,[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),h,4.94,162277,DB00421,Spironolactone
,2080486,mean residence time (MRT),The mean residence time (MRT) of ALT [4.94 +/- 1.14 hours (1 tablet) or 5.31 +/- 1.06 hours (2 tablets)] and SPI [1.81 +/- 0.45 hours (1 tablet) or 1.88 +/- 0.50 hours (2 tablets)] shows a rapid elimination of both drugs.,[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),h,5.31,162278,DB00421,Spironolactone
,2080486,mean residence time (MRT),The mean residence time (MRT) of ALT [4.94 +/- 1.14 hours (1 tablet) or 5.31 +/- 1.06 hours (2 tablets)] and SPI [1.81 +/- 0.45 hours (1 tablet) or 1.88 +/- 0.50 hours (2 tablets)] shows a rapid elimination of both drugs.,[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),h,1.81,162279,DB00421,Spironolactone
,2080486,mean residence time (MRT),The mean residence time (MRT) of ALT [4.94 +/- 1.14 hours (1 tablet) or 5.31 +/- 1.06 hours (2 tablets)] and SPI [1.81 +/- 0.45 hours (1 tablet) or 1.88 +/- 0.50 hours (2 tablets)] shows a rapid elimination of both drugs.,[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),h,1.88,162280,DB00421,Spironolactone
,2080486,MRT,"7TM MRT after administration of 1 or 2 tablets, are 24.51 +/- 15.35 hours and 18.11 +/- 11.87 hours, respectively.",[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),h,24.51,162281,DB00421,Spironolactone
,2080486,MRT,"7TM MRT after administration of 1 or 2 tablets, are 24.51 +/- 15.35 hours and 18.11 +/- 11.87 hours, respectively.",[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),h,18.11,162282,DB00421,Spironolactone
,2080486,MRT,CAN MRT are 39.65 +/- 23.58 hours (1 tablet) and 38.93 +/- 24.58 (2 tablets).,[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),h,39.65,162283,DB00421,Spironolactone
,2080486,MRT,CAN MRT are 39.65 +/- 23.58 hours (1 tablet) and 38.93 +/- 24.58 (2 tablets).,[Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080486/),,38.93,162284,DB00421,Spironolactone
,28814143,overall IC50,"After eight days of dosing, post-adrenocorticotropic hormone challenge plasma aldosterone concentration increase was dose-dependently blunted by LY3045697 with high potency with a dose as low as 0.1 mg resulting in substantial effect, and with an overall IC50 of 0.38 ng/ml.",LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814143/),[ng] / [ml],0.38,164327,DB00421,Spironolactone
,28032902,apparent oral clearance (CL/F),"The population mean of apparent oral clearance (CL/F) in Japanese CHF patients was estimated as 5.31 L/h, which was similar to the mean CL/F for Western CHF patients.",Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28032902/),[l] / [h],5.31,171772,DB00421,Spironolactone
,16948809,tmax,RWJ-351647 had a tmax of 1 to 1.1 h and mean half-life of 10.4-17.4 h.,"Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16948809/),h,1 to 1.1,178046,DB00421,Spironolactone
,16948809,half-life,RWJ-351647 had a tmax of 1 to 1.1 h and mean half-life of 10.4-17.4 h.,"Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16948809/),h,10.4-17.4,178047,DB00421,Spironolactone
,18488807,AUC(0.12),"The AUC(0.12) of spironolactone was 148.35 +/- 39.5 and 144.39 +/- 53.02 ng x h/ml for the test and reference formulation, respectively.",Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18488807/),[h·ng] / [ml],148.35,181364,DB00421,Spironolactone
,18488807,AUC(0.12),"The AUC(0.12) of spironolactone was 148.35 +/- 39.5 and 144.39 +/- 53.02 ng x h/ml for the test and reference formulation, respectively.",Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18488807/),[h·ng] / [ml],144.39,181365,DB00421,Spironolactone
,18488807,AUC(0-60),"The AUC(0-60) of the metabolite canrenone was 1873.36 +/- 318.10 and 1911.28 +/- 355.60 ng h/ml for test and reference formulation, respectively.",Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18488807/),[h·ng] / [ml],1873.36,181366,DB00421,Spironolactone
,18488807,AUC(0-60),"The AUC(0-60) of the metabolite canrenone was 1873.36 +/- 318.10 and 1911.28 +/- 355.60 ng h/ml for test and reference formulation, respectively.",Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18488807/),[h·ng] / [ml],1911.28,181367,DB00421,Spironolactone
,18488807,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) of spironolactone was 48.34 +/- 21.16 ng/ml for the test and 47.40 +/- 23.40 ng/ml for the reference product and the C(max) of the metabolite was 122.90 +/- 27.70 and 123.35 +/- 27.29 ng/ml for the test and reference product, respectively.",Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18488807/),[ng] / [ml],48.34,181368,DB00421,Spironolactone
,18488807,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) of spironolactone was 48.34 +/- 21.16 ng/ml for the test and 47.40 +/- 23.40 ng/ml for the reference product and the C(max) of the metabolite was 122.90 +/- 27.70 and 123.35 +/- 27.29 ng/ml for the test and reference product, respectively.",Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18488807/),[ng] / [ml],47.40,181369,DB00421,Spironolactone
,18488807,C(max),"The maximum plasma concentration (C(max)) of spironolactone was 48.34 +/- 21.16 ng/ml for the test and 47.40 +/- 23.40 ng/ml for the reference product and the C(max) of the metabolite was 122.90 +/- 27.70 and 123.35 +/- 27.29 ng/ml for the test and reference product, respectively.",Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18488807/),[ng] / [ml],122.90,181370,DB00421,Spironolactone
,18488807,C(max),"The maximum plasma concentration (C(max)) of spironolactone was 48.34 +/- 21.16 ng/ml for the test and 47.40 +/- 23.40 ng/ml for the reference product and the C(max) of the metabolite was 122.90 +/- 27.70 and 123.35 +/- 27.29 ng/ml for the test and reference product, respectively.",Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18488807/),[ng] / [ml],123.35,181371,DB00421,Spironolactone
,1884726,relative bioavailability,"The mean relative bioavailability of the spironolactone cyclodextrin complex, compared to the micronised spironolactone powder, was 233%.",Improved bioavailability from a spironolactone beta-cyclodextrin complex. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884726/),%,233,196436,DB00421,Spironolactone
,1884726,area under the serum concentration time curve,Statistical analysis (Wilcoxon signed rank test) revealed that this difference was significant with a mean area under the serum concentration time curve of 3.90 and 1.88 mg.,Improved bioavailability from a spironolactone beta-cyclodextrin complex. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884726/),mg,3.90,196437,DB00421,Spironolactone
,1884726,area under the serum concentration time curve,Statistical analysis (Wilcoxon signed rank test) revealed that this difference was significant with a mean area under the serum concentration time curve of 3.90 and 1.88 mg.,Improved bioavailability from a spironolactone beta-cyclodextrin complex. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884726/),mg,1.88,196438,DB00421,Spironolactone
,1884726,relative bioavailability,"Pharmacokinetic analysis revealed that the mean relative bioavailability of the spironolactone beta cyclodextrin complex and micronised powder when compared with spironolactone tablets (Aldactone) was 252% and 124%, respectively.",Improved bioavailability from a spironolactone beta-cyclodextrin complex. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884726/),%,252,196439,DB00421,Spironolactone
,1884726,relative bioavailability,"Pharmacokinetic analysis revealed that the mean relative bioavailability of the spironolactone beta cyclodextrin complex and micronised powder when compared with spironolactone tablets (Aldactone) was 252% and 124%, respectively.",Improved bioavailability from a spironolactone beta-cyclodextrin complex. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884726/),%,124,196440,DB00421,Spironolactone
,11920745,AUC,"Mean AUC values for EP after infusion through the cephalic vein were 23.0 +/- 2.7 and 18.2 +/- 1.1 h.microg/mL under fasted and fed conditions, respectively.",Atypical dose-route-dependent food effects of eplerenone in the dog: presence of food effects following intravenous dosing and lack of food effects of following oral dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920745/),[h·μg] / [ml],23.0,198291,DB00421,Spironolactone
,11920745,AUC,"Mean AUC values for EP after infusion through the cephalic vein were 23.0 +/- 2.7 and 18.2 +/- 1.1 h.microg/mL under fasted and fed conditions, respectively.",Atypical dose-route-dependent food effects of eplerenone in the dog: presence of food effects following intravenous dosing and lack of food effects of following oral dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920745/),[h·μg] / [ml],18.2,198292,DB00421,Spironolactone
,11920745,AUC,"After oral administration, EP was absorbed 82.0 +/- 6.9 and 98.0 +/- 8.3% under fasted and fed conditions; corresponding mean AUC values were 32.0 +/- 2.0 and 30.8 +/- 3.6 h.microg/mL, respectively.",Atypical dose-route-dependent food effects of eplerenone in the dog: presence of food effects following intravenous dosing and lack of food effects of following oral dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920745/),[h·μg] / [ml],32.0,198293,DB00421,Spironolactone
,11920745,AUC,"After oral administration, EP was absorbed 82.0 +/- 6.9 and 98.0 +/- 8.3% under fasted and fed conditions; corresponding mean AUC values were 32.0 +/- 2.0 and 30.8 +/- 3.6 h.microg/mL, respectively.",Atypical dose-route-dependent food effects of eplerenone in the dog: presence of food effects following intravenous dosing and lack of food effects of following oral dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920745/),[h·μg] / [ml],30.8,198294,DB00421,Spironolactone
,11920745,hepatic first-pass effect,The hepatic first-pass effect of EP was 12.6 +/- 6.3% under fasted conditions and 27.1 +/- 6.0% under fed conditions.,Atypical dose-route-dependent food effects of eplerenone in the dog: presence of food effects following intravenous dosing and lack of food effects of following oral dosing. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920745/),%,12.6,198295,DB00421,Spironolactone
,11920745,hepatic first-pass effect,The hepatic first-pass effect of EP was 12.6 +/- 6.3% under fasted conditions and 27.1 +/- 6.0% under fed conditions.,Atypical dose-route-dependent food effects of eplerenone in the dog: presence of food effects following intravenous dosing and lack of food effects of following oral dosing. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920745/),%,27.1,198296,DB00421,Spironolactone
,3769384,AUC (0 to 24 hours),"By taking spironolactone with food, the mean (+/- SD) AUC (0 to 24 hours) of the parent drug increased from 288 +/- 138 (empty stomach) to 493 +/- 105 ng X ml-1 X hr (P less than 0.001).",Influence of food on the bioavailability of spironolactone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769384/),[h·ng] / [ml],288,199292,DB00421,Spironolactone
,3769384,AUC (0 to 24 hours),"By taking spironolactone with food, the mean (+/- SD) AUC (0 to 24 hours) of the parent drug increased from 288 +/- 138 (empty stomach) to 493 +/- 105 ng X ml-1 X hr (P less than 0.001).",Influence of food on the bioavailability of spironolactone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769384/),[h·ng] / [ml],493,199293,DB00421,Spironolactone
,3769384,AUC (0 to 24 hours),The AUC (0 to 24 hours) of the three metabolites together also increased significantly from 8511 +/- 2062 (empty stomach) to 11219 +/- 2471 ng X ml-1 X hr (P less than 0.01).,Influence of food on the bioavailability of spironolactone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769384/),[h·ng] / [ml],8511,199294,DB00421,Spironolactone
,3769384,AUC (0 to 24 hours),The AUC (0 to 24 hours) of the three metabolites together also increased significantly from 8511 +/- 2062 (empty stomach) to 11219 +/- 2471 ng X ml-1 X hr (P less than 0.01).,Influence of food on the bioavailability of spironolactone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769384/),[h·ng] / [ml],11219,199295,DB00421,Spironolactone
,14570778,Cmax,"EP was well absorbed, and a mean EP Cmax of 1.72 mug/ml was achieved 1.2 h postdose.",Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570778/),[μg] / [ml],1.72,200803,DB00421,Spironolactone
,14570778,half-life,"After the Cmax, plasma concentrations of EP declined with a half-life of 3.0 h.",Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570778/),h,3.0,200804,DB00421,Spironolactone
,14570778,Plasma protein binding,Plasma protein binding was moderate (33-60%) but concentration-dependent over the therapeutic concentration range.,Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570778/),%,33-60,200805,DB00421,Spironolactone
,7456563,Sodium/potassium ratio,"Sodium/potassium ratio was 5.9 during the first 8 hours, and the mean ratio was 5.2 during 24 hours.",[Pharmacodynamic and pharmacokinetic studies of muzolimine in patients with hepatogeneous ascites (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7456563/),,5.9,200924,DB00421,Spironolactone
,7456563,ratio,"Sodium/potassium ratio was 5.9 during the first 8 hours, and the mean ratio was 5.2 during 24 hours.",[Pharmacodynamic and pharmacokinetic studies of muzolimine in patients with hepatogeneous ascites (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7456563/),,5.2,200925,DB00421,Spironolactone
,7456563,plasma half-life,Mean plasma half-life of muzolimine in these patients with liver cirrhosis was 7.9 h and was thus longer than in healthy volunteers.,[Pharmacodynamic and pharmacokinetic studies of muzolimine in patients with hepatogeneous ascites (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7456563/),h,7.9,200926,DB00421,Spironolactone
,11976,absolute bioavailability,"The absolute bioavailability of a pharmacologically active metabolite, canrenone, was 57% in the dog and 48% in the monkey.",Species differences in the metabolism and disposition of spironolactone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,57,210401,DB00421,Spironolactone
,11976,absolute bioavailability,"The absolute bioavailability of a pharmacologically active metabolite, canrenone, was 57% in the dog and 48% in the monkey.",Species differences in the metabolism and disposition of spironolactone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,48,210402,DB00421,Spironolactone
,11976,excretion,"The cumulative average excretion of radioactivity in the urine as percentage of the po dose in 6 days was 4.69% in the rat (N = 5), 18.5% in the dog (N = 3), and 46.0% in the monkey (N = 3).",Species differences in the metabolism and disposition of spironolactone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,4.69,210403,DB00421,Spironolactone
,11976,excretion,"The cumulative average excretion of radioactivity in the urine as percentage of the po dose in 6 days was 4.69% in the rat (N = 5), 18.5% in the dog (N = 3), and 46.0% in the monkey (N = 3).",Species differences in the metabolism and disposition of spironolactone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,18.5,210404,DB00421,Spironolactone
,11976,excretion,"The cumulative average excretion of radioactivity in the urine as percentage of the po dose in 6 days was 4.69% in the rat (N = 5), 18.5% in the dog (N = 3), and 46.0% in the monkey (N = 3).",Species differences in the metabolism and disposition of spironolactone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,46.0,210405,DB00421,Spironolactone
,11976,excretion,"In the feces, the corresponding excretion values were 74.2, 69.3 and 40.1%, respectively.",Species differences in the metabolism and disposition of spironolactone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,74.2,210406,DB00421,Spironolactone
,11976,excretion,"In the feces, the corresponding excretion values were 74.2, 69.3 and 40.1%, respectively.",Species differences in the metabolism and disposition of spironolactone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,69.3,210407,DB00421,Spironolactone
,11976,excretion,"In the feces, the corresponding excretion values were 74.2, 69.3 and 40.1%, respectively.",Species differences in the metabolism and disposition of spironolactone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,40.1,210408,DB00421,Spironolactone
,11976,excretion,"Canrenone excretion in the urine constituted 0.65% of the po dose in the rat, 0.82% in the dog, and 5.86% in the monkey, whereas the excretion of total fluorogenic metabolites constituted 1.1, 1.9, and 12.1% respectively.",Species differences in the metabolism and disposition of spironolactone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,0,210409,DB00421,Spironolactone
,11976,excretion,"Canrenone excretion in the urine constituted 0.65% of the po dose in the rat, 0.82% in the dog, and 5.86% in the monkey, whereas the excretion of total fluorogenic metabolites constituted 1.1, 1.9, and 12.1% respectively.",Species differences in the metabolism and disposition of spironolactone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,0.82,210410,DB00421,Spironolactone
,11976,excretion,"Canrenone excretion in the urine constituted 0.65% of the po dose in the rat, 0.82% in the dog, and 5.86% in the monkey, whereas the excretion of total fluorogenic metabolites constituted 1.1, 1.9, and 12.1% respectively.",Species differences in the metabolism and disposition of spironolactone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,5.86,210411,DB00421,Spironolactone
,11976,excretion,"Canrenone excretion in the urine constituted 0.65% of the po dose in the rat, 0.82% in the dog, and 5.86% in the monkey, whereas the excretion of total fluorogenic metabolites constituted 1.1, 1.9, and 12.1% respectively.",Species differences in the metabolism and disposition of spironolactone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,1.1,210412,DB00421,Spironolactone
,11976,excretion,"Canrenone excretion in the urine constituted 0.65% of the po dose in the rat, 0.82% in the dog, and 5.86% in the monkey, whereas the excretion of total fluorogenic metabolites constituted 1.1, 1.9, and 12.1% respectively.",Species differences in the metabolism and disposition of spironolactone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,1.9,210413,DB00421,Spironolactone
,11976,excretion,"Canrenone excretion in the urine constituted 0.65% of the po dose in the rat, 0.82% in the dog, and 5.86% in the monkey, whereas the excretion of total fluorogenic metabolites constituted 1.1, 1.9, and 12.1% respectively.",Species differences in the metabolism and disposition of spironolactone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976/),%,12.1,210414,DB00421,Spironolactone
,2723123,Peak serum levels,"Peak serum levels [mean (SD)] of spironolactone, canrenone, and sulfur-containing metabolites IV and V were 72 (45), 155 (43), 359 (106) and 101 (26) ng/ml, respectively on day 1 and 80 (20), 181 (39), 391 (118) and 125 (24) ng/ml, respectively on day 15.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),[ng] / [ml],72,212106,DB00421,Spironolactone
,2723123,Peak serum levels,"Peak serum levels [mean (SD)] of spironolactone, canrenone, and sulfur-containing metabolites IV and V were 72 (45), 155 (43), 359 (106) and 101 (26) ng/ml, respectively on day 1 and 80 (20), 181 (39), 391 (118) and 125 (24) ng/ml, respectively on day 15.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),[ng] / [ml],155,212107,DB00421,Spironolactone
,2723123,Peak serum levels,"Peak serum levels [mean (SD)] of spironolactone, canrenone, and sulfur-containing metabolites IV and V were 72 (45), 155 (43), 359 (106) and 101 (26) ng/ml, respectively on day 1 and 80 (20), 181 (39), 391 (118) and 125 (24) ng/ml, respectively on day 15.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),[ng] / [ml],359,212108,DB00421,Spironolactone
,2723123,Peak serum levels,"Peak serum levels [mean (SD)] of spironolactone, canrenone, and sulfur-containing metabolites IV and V were 72 (45), 155 (43), 359 (106) and 101 (26) ng/ml, respectively on day 1 and 80 (20), 181 (39), 391 (118) and 125 (24) ng/ml, respectively on day 15.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),[ng] / [ml],101,212109,DB00421,Spironolactone
,2723123,Peak serum levels,"Peak serum levels [mean (SD)] of spironolactone, canrenone, and sulfur-containing metabolites IV and V were 72 (45), 155 (43), 359 (106) and 101 (26) ng/ml, respectively on day 1 and 80 (20), 181 (39), 391 (118) and 125 (24) ng/ml, respectively on day 15.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),[ng] / [ml],80,212110,DB00421,Spironolactone
,2723123,Peak serum levels,"Peak serum levels [mean (SD)] of spironolactone, canrenone, and sulfur-containing metabolites IV and V were 72 (45), 155 (43), 359 (106) and 101 (26) ng/ml, respectively on day 1 and 80 (20), 181 (39), 391 (118) and 125 (24) ng/ml, respectively on day 15.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),[ng] / [ml],181,212111,DB00421,Spironolactone
,2723123,Peak serum levels,"Peak serum levels [mean (SD)] of spironolactone, canrenone, and sulfur-containing metabolites IV and V were 72 (45), 155 (43), 359 (106) and 101 (26) ng/ml, respectively on day 1 and 80 (20), 181 (39), 391 (118) and 125 (24) ng/ml, respectively on day 15.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),[ng] / [ml],391,212112,DB00421,Spironolactone
,2723123,Peak serum levels,"Peak serum levels [mean (SD)] of spironolactone, canrenone, and sulfur-containing metabolites IV and V were 72 (45), 155 (43), 359 (106) and 101 (26) ng/ml, respectively on day 1 and 80 (20), 181 (39), 391 (118) and 125 (24) ng/ml, respectively on day 15.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),[ng] / [ml],125,212113,DB00421,Spironolactone
,2723123,AUC (0-24),"The AUC (0-24) values of these compounds on day 15 were 231 (50), 2173 (312), 2804 (777) and 1727 (367) ng.hr/ml, respectively and the post-steady state elimination half-life (t1/2) values were 1.4 (0.5), 16.5 (6.3), 13.8 (6.4), and 15.0 (4.0) hours, respectively.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),[h·ng] / [ml],231,212114,DB00421,Spironolactone
,2723123,AUC (0-24),"The AUC (0-24) values of these compounds on day 15 were 231 (50), 2173 (312), 2804 (777) and 1727 (367) ng.hr/ml, respectively and the post-steady state elimination half-life (t1/2) values were 1.4 (0.5), 16.5 (6.3), 13.8 (6.4), and 15.0 (4.0) hours, respectively.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),[h·ng] / [ml],2173,212115,DB00421,Spironolactone
,2723123,AUC (0-24),"The AUC (0-24) values of these compounds on day 15 were 231 (50), 2173 (312), 2804 (777) and 1727 (367) ng.hr/ml, respectively and the post-steady state elimination half-life (t1/2) values were 1.4 (0.5), 16.5 (6.3), 13.8 (6.4), and 15.0 (4.0) hours, respectively.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),[h·ng] / [ml],2804,212116,DB00421,Spironolactone
,2723123,AUC (0-24),"The AUC (0-24) values of these compounds on day 15 were 231 (50), 2173 (312), 2804 (777) and 1727 (367) ng.hr/ml, respectively and the post-steady state elimination half-life (t1/2) values were 1.4 (0.5), 16.5 (6.3), 13.8 (6.4), and 15.0 (4.0) hours, respectively.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),[h·ng] / [ml],1727,212117,DB00421,Spironolactone
,2723123,post-steady state elimination half-life (t1/2),"The AUC (0-24) values of these compounds on day 15 were 231 (50), 2173 (312), 2804 (777) and 1727 (367) ng.hr/ml, respectively and the post-steady state elimination half-life (t1/2) values were 1.4 (0.5), 16.5 (6.3), 13.8 (6.4), and 15.0 (4.0) hours, respectively.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),h,1.4,212118,DB00421,Spironolactone
,2723123,post-steady state elimination half-life (t1/2),"The AUC (0-24) values of these compounds on day 15 were 231 (50), 2173 (312), 2804 (777) and 1727 (367) ng.hr/ml, respectively and the post-steady state elimination half-life (t1/2) values were 1.4 (0.5), 16.5 (6.3), 13.8 (6.4), and 15.0 (4.0) hours, respectively.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),h,16.5,212119,DB00421,Spironolactone
,2723123,post-steady state elimination half-life (t1/2),"The AUC (0-24) values of these compounds on day 15 were 231 (50), 2173 (312), 2804 (777) and 1727 (367) ng.hr/ml, respectively and the post-steady state elimination half-life (t1/2) values were 1.4 (0.5), 16.5 (6.3), 13.8 (6.4), and 15.0 (4.0) hours, respectively.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),h,13.8,212120,DB00421,Spironolactone
,2723123,post-steady state elimination half-life (t1/2),"The AUC (0-24) values of these compounds on day 15 were 231 (50), 2173 (312), 2804 (777) and 1727 (367) ng.hr/ml, respectively and the post-steady state elimination half-life (t1/2) values were 1.4 (0.5), 16.5 (6.3), 13.8 (6.4), and 15.0 (4.0) hours, respectively.",Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723123/),h,15.0,212121,DB00421,Spironolactone
,9680070,Half-lives,"Half-lives for spironolactone, 7alpha-thiomethylspirolactone and canrenone were 0.72 +/- 0.17, 1.5 +/- 0.3 and 2.2 +/- 0.3 h, respectively.",Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9680070/),h,0.72,225981,DB00421,Spironolactone
,9680070,Half-lives,"Half-lives for spironolactone, 7alpha-thiomethylspirolactone and canrenone were 0.72 +/- 0.17, 1.5 +/- 0.3 and 2.2 +/- 0.3 h, respectively.",Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9680070/),h,1.5,225982,DB00421,Spironolactone
,9680070,Half-lives,"Half-lives for spironolactone, 7alpha-thiomethylspirolactone and canrenone were 0.72 +/- 0.17, 1.5 +/- 0.3 and 2.2 +/- 0.3 h, respectively.",Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9680070/),h,2.2,225983,DB00421,Spironolactone
,9680070,bioavailabilities,"After oral administration of spironolactone the bioavailabilities evaluated from the AUC values of 7alpha-thiomethylspirolactone were 27.5 +/- 9.3%, 81.3 +/- 28.8% and 82.8 +/- 28.6% for powder papers, DM-beta-CyD and SBE7 solutions, respectively.",Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9680070/),%,27.5,225984,DB00421,Spironolactone
,9680070,bioavailabilities,"After oral administration of spironolactone the bioavailabilities evaluated from the AUC values of 7alpha-thiomethylspirolactone were 27.5 +/- 9.3%, 81.3 +/- 28.8% and 82.8 +/- 28.6% for powder papers, DM-beta-CyD and SBE7 solutions, respectively.",Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9680070/),%,81.3,225985,DB00421,Spironolactone
,9680070,bioavailabilities,"After oral administration of spironolactone the bioavailabilities evaluated from the AUC values of 7alpha-thiomethylspirolactone were 27.5 +/- 9.3%, 81.3 +/- 28.8% and 82.8 +/- 28.6% for powder papers, DM-beta-CyD and SBE7 solutions, respectively.",Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9680070/),%,82.8,225986,DB00421,Spironolactone
,6519151,half-life (t1/2 alpha),"From our eight normal subjects studied, the harmonic mean of the distributive half-life (t1/2 alpha) of canrenone was found to be 1.66 h, and the harmonic mean of the terminal elimination half-life (t1/2 beta) to be 22.6 h.",Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519151/),h,1.66,240510,DB00421,Spironolactone
,6519151,terminal elimination half-life (t1/2 beta),"From our eight normal subjects studied, the harmonic mean of the distributive half-life (t1/2 alpha) of canrenone was found to be 1.66 h, and the harmonic mean of the terminal elimination half-life (t1/2 beta) to be 22.6 h.",Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519151/),h,22.6,240511,DB00421,Spironolactone
,6519151,di,Harmonic means of the distributive and elimination half-lives of 'total metabolites' after base hydrolysis were 2.48 h and 28.8 h respectively.,Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519151/),h,2.48,240512,DB00421,Spironolactone
,6519151,elimination half-lives,Harmonic means of the distributive and elimination half-lives of 'total metabolites' after base hydrolysis were 2.48 h and 28.8 h respectively.,Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519151/),h,28.8,240513,DB00421,Spironolactone
,6519151,accumulation ratio,"The accumulation ratio of canrenone was 2.53, whereas that of 'total metabolites' was 1.89.",Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519151/),,2.53,240514,DB00421,Spironolactone
,6519151,accumulation ratio,"The accumulation ratio of canrenone was 2.53, whereas that of 'total metabolites' was 1.89.",Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519151/),,1.89,240515,DB00421,Spironolactone
,32798059,CL/F,"The typical population value of digoxin CL/F was 5.06 L/h, and the volume of distribution was 211.82 L.","Impact of SLCO4C1 Genotypes, Creatinine, and Spironolactone on Digoxin Population Pharmacokinetic Variables in Patients With Cardiac Insufficiency. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32798059/),[l] / [h],5.06,245454,DB00421,Spironolactone
,32798059,volume of distribution,"The typical population value of digoxin CL/F was 5.06 L/h, and the volume of distribution was 211.82 L.","Impact of SLCO4C1 Genotypes, Creatinine, and Spironolactone on Digoxin Population Pharmacokinetic Variables in Patients With Cardiac Insufficiency. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32798059/),l,211.82,245455,DB00421,Spironolactone
,23096939,apparent clearance (CL/F),"The typical values with interindividual variability for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 8.9 L h(-1) (43.2 %) and 420 L (65.8 %), respectively.",Population pharmacokinetics of digoxin in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23096939/),[l] / [h],8.9,248836,DB00421,Spironolactone
,23096939,apparent volume of distribution (V/F),"The typical values with interindividual variability for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 8.9 L h(-1) (43.2 %) and 420 L (65.8 %), respectively.",Population pharmacokinetics of digoxin in elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23096939/),l,420,248837,DB00421,Spironolactone
greater,1629288,Recoveries,Recoveries for all analytes were greater than 80% in plasma and 72% in urine.,High-performance liquid chromatographic determination of spironolactone and its metabolites in human biological fluids after solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629288/),%,80,271918,DB00421,Spironolactone
,1629288,Recoveries,Recoveries for all analytes were greater than 80% in plasma and 72% in urine.,High-performance liquid chromatographic determination of spironolactone and its metabolites in human biological fluids after solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629288/),%,72,271919,DB00421,Spironolactone
